Canagliflozin - Johnson & Johnson/Mitsubishi Tanabe Pharma Corporation
Alternative Names: Canagliflozin-hydrate; Canaglu; Invokana; JNJ-28431754; Sulisent; TA-7284Latest Information Update: 29 May 2024
At a glance
- Originator Tanabe Seiyaku
- Developer Daiichi Sankyo Company; Janssen; Johnson & Johnson; Mitsubishi Tanabe Pharma Corporation; Miyazaki University School of Medicine; Mundipharma Medical Company; Tai Tien Pharmaceuticals
- Class Antihyperglycaemics; Cardiovascular therapies; Glucosides; Heart failure therapies; Obesity therapies; Small molecules; Thiophenes
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diabetic nephropathies; Type 2 diabetes mellitus
- Phase III Heart failure
- Phase II Obesity; Type 1 diabetes mellitus